New pill HRS-1893 tested for stiff heart condition

NCT ID NCT07269717

Recruiting now Symptom relief Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called HRS-1893 in 48 adults with heart failure where the heart pumps normally but is too stiff (heart failure with preserved ejection fraction). The main goal is to check safety and side effects, while also looking at changes in heart stress markers and symptom scores. Participants will receive either the drug or a placebo for a set period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-1893 tablet
What this could lead to: If successful, this could point toward a new treatment option to ease symptoms and improve quality of life for people with a common type of heart failure.
What could go wrong: This is a small, early-phase trial focused on safety, not proof of effectiveness. The drug may not show meaningful benefits or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

Contacts and locations

Locations

Zhongshan Hospital Affiliated to Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.